Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.

Seelig E, Howlett J, Porter L, Truman L, Heywood J, Kennet J, Arbon EL, Anselmiova K, Walker NM, Atkar R, Pekalski ML, Rytina E, Evans M, Wicker LS, Todd JA, Mander AP, Bond S, Waldron-Lynch F.

JCI Insight. 2018 Oct 4;3(19). pii: 99306. doi: 10.1172/jci.insight.99306.


Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.

Cutler AJ, Oliveira J, Ferreira RC, Challis B, Walker NM, Caddy S, Lu J, Stevens HE, Smyth DJ, Pekalski ML, Kennet J, Hunter KMD, Goodfellow I, Wicker LS, Todd JA, Waldron-Lynch F.

Wellcome Open Res. 2017 Oct 5;2:28. doi: 10.12688/wellcomeopenres.11300.3. eCollection 2017.


Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

Pekalski ML, García AR, Ferreira RC, Rainbow DB, Smyth DJ, Mashar M, Brady J, Savinykh N, Dopico XC, Mahmood S, Duley S, Stevens HE, Walker NM, Cutler AJ, Waldron-Lynch F, Dunger DB, Shannon-Lowe C, Coles AJ, Jones JL, Wallace C, Todd JA, Wicker LS.

JCI Insight. 2017 Aug 17;2(16). pii: 93739. doi: 10.1172/jci.insight.93739. eCollection 2017 Aug 17.


In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment.

Ferreira RC, Rainbow DB, Rubio García A, Pekalski ML, Porter L, Oliveira JJ, Waldron-Lynch F, Wicker LS, Todd JA.

Data Brief. 2017 May 2;12:676-691. doi: 10.1016/j.dib.2017.04.043. eCollection 2017 Jun.


Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.

Ferreira RC, Rainbow DB, Rubio García A, Pekalski ML, Porter L, Oliveira JJ, Waldron-Lynch F, Wicker LS, Todd JA.

Clin Immunol. 2017 Jun;179:25-39. doi: 10.1016/j.clim.2017.03.002. Epub 2017 Mar 9.


Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.

Todd JA, Evangelou M, Cutler AJ, Pekalski ML, Walker NM, Stevens HE, Porter L, Smyth DJ, Rainbow DB, Ferreira RC, Esposito L, Hunter KM, Loudon K, Irons K, Yang JH, Bell CJ, Schuilenburg H, Heywood J, Challis B, Neupane S, Clarke P, Coleman G, Dawson S, Goymer D, Anselmiova K, Kennet J, Brown J, Caddy SL, Lu J, Greatorex J, Goodfellow I, Wallace C, Tree TI, Evans M, Mander AP, Bond S, Wicker LS, Waldron-Lynch F.

PLoS Med. 2016 Oct 11;13(10):e1002139. doi: 10.1371/journal.pmed.1002139. eCollection 2016 Oct.


Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.

Truman LA, Pekalski ML, Kareclas P, Evangelou M, Walker NM, Howlett J, Mander AP, Kennet J, Wicker LS, Bond S, Todd JA, Waldron-Lynch F.

BMJ Open. 2015 Dec 8;5(12):e009799. doi: 10.1136/bmjopen-2015-009799.


Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).

Heywood J, Evangelou M, Goymer D, Kennet J, Anselmiova K, Guy C, O'Brien C, Nutland S, Brown J, Walker NM, Todd JA, Waldron-Lynch F.

Trials. 2015 Mar 11;16:86. doi: 10.1186/s13063-015-0583-7.


Humanized mice as a model for aberrant responses in human T cell immunotherapy.

Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ, Herold KC.

J Immunol. 2014 Jul 15;193(2):587-96. doi: 10.4049/jimmunol.1302455. Epub 2014 Jun 18.


Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.

Waldron-Lynch F, Kareclas P, Irons K, Walker NM, Mander A, Wicker LS, Todd JA, Bond S.

BMJ Open. 2014 Jun 4;4(6):e005559. doi: 10.1136/bmjopen-2014-005559.


Immunological biomarkers: catalysts for translational advances in autoimmune diabetes.

Ahmed ST, Akirav E, Bradshaw E, Buckner J, McKinney E, Quintana FJ, Waldron-Lynch F, Nepom J.

Clin Exp Immunol. 2013 May;172(2):178-85. doi: 10.1111/cei.12063.


Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA.

Diabetologia. 2013 Feb;56(2):391-400. doi: 10.1007/s00125-012-2753-4. Epub 2012 Oct 21.


Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma.

Waldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-Hurlburt P, Hui P, McClaskey J, Hagopian WA, Meffre E, Marks PW, Wen L, Herold KC.

J Clin Endocrinol Metab. 2012 Dec;97(12):4317-23. doi: 10.1210/jc.2012-2388. Epub 2012 Oct 16.


Analysis of human biologics with a mouse skin transplant model in humanized mice.

Waldron-Lynch F, Deng S, Preston-Hurlburt P, Henegariu O, Herold KC.

Am J Transplant. 2012 Oct;12(10):2652-62. doi: 10.1111/j.1600-6143.2012.04178.x. Epub 2012 Aug 17.


New and future immunomodulatory therapy in type 1 diabetes.

Tooley JE, Waldron-Lynch F, Herold KC.

Trends Mol Med. 2012 Mar;18(3):173-81. doi: 10.1016/j.molmed.2012.01.001. Epub 2012 Feb 17. Review.


Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, Herold KC.

Sci Transl Med. 2012 Jan 25;4(118):118ra12. doi: 10.1126/scitranslmed.3003401.


Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Waldron-Lynch F, Herold KC.

Nat Rev Drug Discov. 2011 Jun;10(6):439-52. doi: 10.1038/nrd3402. Review.


Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage.

Waldron-Lynch F, Herold KC.

Endocrinol Metab Clin North Am. 2009 Jun;38(2):303-17, viii. doi: 10.1016/j.ecl.2009.01.005. Review.


High bone turnover in Irish professional jockeys.

Waldron-Lynch F, Murray BF, Brady JJ, McKenna MJ, McGoldrick A, Warrington G, O'Loughlin G, Barragry JM.

Osteoporos Int. 2010 Mar;21(3):521-5. doi: 10.1007/s00198-009-0887-0. Epub 2009 Mar 7.


Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.

Waldron-Lynch F, von Herrath M, Herold KC.

Novartis Found Symp. 2008;292:146-55; discussion 155-8, 202-3.


When a nephrectomy cures hypoglycaemia.

O'Loughlin A, Waldron-Lynch F, Cronin KC, Dinneen S, Lee J, Griffin D, Casey M, Nusrat N, Jaffrey S, O'Brien T, Dunne F.

BMJ Case Rep. 2009;2009:bcr0220091617. doi: 10.1136/bcr.02.2009.1617. Epub 2009 May 17.


Continuous glucose monitoring: long live the revolution!

Waldron-Lynch F, Herold KC.

Nat Clin Pract Endocrinol Metab. 2009 Feb;5(2):82-3. doi: 10.1038/ncpendmet1044. Epub 2008 Dec 17. No abstract available.


Dress and address: patient preferences regarding doctor's style of dress and patient interaction.

Gallagher J, Waldron Lynch F, Stack J, Barragry J.

Ir Med J. 2008 Jul-Aug;101(7):211-3.


Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain.

Dinneen SF, Waldron-Lynch F.

Evid Based Med. 2008 Jun;13(3):77. doi: 10.1136/ebm.13.3.77. No abstract available.


Self-monitoring of blood glucose did not improve glycaemic control in patients with type 2 diabetes not treated with insulin.

Waldron-Lynch F, Dinneen S.

Evid Based Med. 2008 Feb;13(1):7. doi: 10.1136/ebm.13.1.7. No abstract available.


Self-monitoring of blood glucose did not improve glycemic control in patients with type 2 diabetes not treated with insulin.

Waldron-Lynch F, Dinneen S.

ACP J Club. 2008 Jan-Feb;148(1):1. No abstract available.


When a stroke is not a stroke; posterior leukoencephalopathy syndrome mimicking posterior circulation stroke.

Waldron-Lynch F, Meehan C, Roche C, Murphy J, Hennessy M, Counihan TJ.

Ir Med J. 2007 Jan;100(1):334-6.


Immunopathogenesis of multiple sclerosis: implications for treatment.

Waldron-Lynch F, Hennessy MJ.

Ir Med J. 2004 Jan;97(1):5-6. No abstract available.


Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.

Houston A, Waldron-Lynch FD, Bennett MW, Roche D, O'Sullivan GC, Shanahan F, O'Connell J.

Int J Cancer. 2003 Nov 1;107(2):209-14.


Detection of single nucleotide polymorphisms using a non-isotopic RNase cleavage assay.

Waldron-Lynch F, Adams C, Molloy MG, O'Gara F.

Methods Mol Biol. 2002;193:253-63. No abstract available.


Tumour necrosis factor 5' promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families.

Waldron-Lynch F, Adams C, Amos C, Zhu DK, McDermott MF, Shanahan F, Molloy MG, O'Gara F.

Genes Immun. 2001 Apr;2(2):82-7.


Modelling the major histocompatibility complex susceptibility to RA using the MASC method.

Génin E, Babron MC, McDermott MF, Mulcahy B, Waldron-Lynch F, Adams C, Clegg DO, Ward RH, Shanahan F, Molloy MG, O'Gara F, Clerget-Darpoux F.

Genet Epidemiol. 1998;15(4):419-30.


Exclusion of the familial Mediterranean fever locus as a susceptibility region for autosomal dominant familial Hibernian fever.

McDermott MF, McDermott EM, Quane KA, Jones LC, Ogunkolade BW, Curtis D, Waldron-Lynch F, Phelan M, Hitman GA, Molloy MG, Powell RJ.

J Med Genet. 1998 May;35(5):432-4.


Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.

Mulcahy B, Waldron-Lynch F, McDermott MF, Adams C, Amos CI, Zhu DK, Ward RH, Clegg DO, Shanahan F, Molloy MG, O'Gara F.

Am J Hum Genet. 1996 Sep;59(3):676-83.

Supplemental Content

Loading ...
Support Center